The optimal range of serum intact parathyroid hormone for a lower risk of mortality in the incident hemodialysis patients

Xiaoling Zhou, Yidan Guo and Yang Luo

Department of Nephrology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China

ABSTRACT

The serum intact parathyroid hormone (iPTH) is associated with the prognosis of hemodialysis (HD) patients, however, its optimal range for reducing mortality remains inconsistent. We designed a prospective cohort study of 346 incident HD patients to assess the association between different serum iPTH level and mortality. According to the Kidney Disease Outcomes Quality Initiative (K/DOQI) international guidelines (2003), we divided patients into three groups (iPTH < 150 pg/mL, 150–300 pg/mL and >300 pg/mL). During the median follow-up of 58 months, 157 patients (45.38%) died. Multivariate Cox regression analysis showed that iPTH < 150 pg/mL and >300 pg/mL were associated with all-cause and cardiovascular mortality. Then, we performed a sensitivity analysis of patients divided into 6 serum PTH levels groups according to the folds of the K/DOQI target range. Multivariate Cox regression analysis showed that patients with serum iPTH/C21750 pg/mL, 600–749 pg/mL, 450–599 pg/mL had significantly higher risk of all-cause and cardiovascular mortality compared with those with serum iPTH in the range of 150–299 pg/mL. The association between serum iPTH and mortality shows a U-shaped curve. The optimal serum iPTH level which confers the lowest risk of all-cause and cardiovascular mortality could range from 150 pg/mL to 450 pg/mL in this group of incident HD patients.

ARTICLE HISTORY

Received 16 November 2020
Revised 9 March 2021
Accepted 9 March 2021

KEYWORDS

Parathyroid hormone; mortality; dialysis; chronic kidney disease-mineral and bone disorder

Introduction

Despite therapeutic development, chronic kidney disease-mineral and bone disorder (CKD-MBD) is still a critical issue among patients undergoing hemodialysis (HD) [1–4]. Several large observational studies have indicated that the occurrence of CKD-MBD is associated with an increased risk of mortality [5–9]. In 2003, the US National Kidney Foundation implemented the Kidney Disease Outcomes Quality Initiative (K/DOQI) international guidelines to establish target levels for serum intact parathyroid hormone (iPTH), calcium (Ca), and phosphorus (P) to help lower the CKD-MBD-related mortality. However, evidence suggested that this restrictive guideline was difficult to achieve, especially over the long term of HD treatment [10–13].

After that guideline was recommended, the Kidney Disease Improving Global Outcomes (KDIGO) published a new CKD-MBD guideline in 2009. The guideline suggested maintaining serum iPTH level in the range of approximately two to nine times the upper normal limit for the assay (2 C) [14]. Since the guideline was implemented, there has been an increased awareness of CKD-MBD, however, the level of evidence for this iPTH level recommendation is only C, which indicates a lack about the impact of different levels of serum iPTH on mortality. Also, the suggested wide range of serum iPTH levels (2–9 fold) in the guideline is difficult to apply for health providers in their clinical settings [15,16].

To better quantify the optimal levels of serum iPTH for a lower risk of mortality, we examined the association between different serum iPTH levels and mortality among a group of incident HD patients. We hypothesized that there would be a different risk of mortality among HD patients with different levels of serum iPTH.

Materials and methods

Study design and population

The study protocol was approved by the Institutional Ethical Review Board of Beijing Shijitan Hospital, Capital Medical University (SJT2020-18), and the procedures were conducted in following the Good Clinical Practice
and the Declaration of Helsinki on biomedical research involving human subjects. All participants provided informed consent.

The study participants were hemodialysis patients recruited from the dialysis center of Beijing Shijitan Hospital, Capital Medical University between April 2010 and June 2015. The inclusion criteria were as follows: (1) age ≥18 years, (2) newly diagnosed with end-stage renal disease (ESRD) and starting hemodialysis for 3 months. The exclusion criteria were: (1) unwilling to provide written informed consent, (2) inadequate baseline data available for analysis.

**Data collection and laboratory measurements**

After enrollment, we collected the participants’ demographic data, smoking habits, body mass index (BMI), the etiology of ESRD, comorbidities, medications with outcome influences, and type of vascular access. The blood tests included measurement of the serum levels of hemoglobin, albumin, triglycerides, total cholesterol, high sensitivity C-reactive protein (hs-CRP), calcium, phosphate, iPTH, and 25(OH)VitD. Blood samples were collected on the day of the first dialysis session in a week. Serum iPTH was measured by an electro chemiluminescence immunoassay run on a DXI800 auto analyzer (Beckman Coulter, CA, USA; reference range 15–75 pg/mL). Urea clearance index single-pool $K_\text{f}/V$ (sp $K_\text{f}/V$) was calculated by the pre- and post-dialysis serum urea nitrogen levels. The estimated glomerular filtration rate (eGFR) was calculated by a modified Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula with an adjusted coefficient of 1.1 for the Chinese population [17].

**Outcome measurements**

The primary outcomes were all-cause mortality and cardiovascular disease (CVD) mortality. The CVD mortality was defined as death from CVD including sudden cardiac death, myocardial infarction, congestive heart failure, and stroke. Survival time was defined as the time elapsed from initial study enrollment until death, modality switch to peritoneal dialysis, kidney transplantation, or the end of the study period (31 January 2020).

**Statistical methods**

We used IBM SPSS Statistics 21.0 (IBM Corp., Armonk, NY) to perform the analyses. Descriptive analysis, including proportions, means, and frequencies, was used to define participant characteristics. Continuous variables were expressed as mean with standard deviation (SD) or median with interquartile range (IQR); categorical variables were expressed as a number with a percentage. Comparisons between groups were performed with one-way ANOVA for normally distributed continuous variables or Kruskal-Wallis H tests for skew distributed continuous variables, and Chi-square test for categorical data.

We generated univariate and multivariable Cox proportional hazards regression analysis to determine the crude and adjusted hazard ratios (HR) for all-cause mortality and CVD mortality. The multivariable Cox analysis was adjusted for demographic characteristics (age, gender), BMI, comorbidities (diabetes, hypertension), MBD-related medications (phosphate binders, vitamin D, and Cinacalcet), type of vascular access, laboratory parameters (hemoglobin, albumin, triglycerides, total cholesterol, hs-CRP, calcium, phosphate, iPTH, 25(OH)VitD), eGFR, and dialysis parameters (sp $K_\text{f}/V$). In the adjustment analysis, serum iPTH, calcium, and phosphate were divided into clinically relevant categories according to the K/DOQI [10] target ranges. Serum iPTH 150–300 pg/mL, serum calcium 2.10–2.37 mmol/L, and phosphate 1.13–1.78 mmol/L were used as a reference, respectively.

We also performed a sensitivity analysis of patients divided into six groups of different serum iPTH levels according to the folds of the K/DOQI target range of serum iPTH, i.e. serum iPTH < 150 pg/mL, 150–299 pg/mL, 300–449 pg/mL, 450–599 pg/mL, 600–749 pg/mL, and ≥750 pg/mL, respectively. We repeated the multivariable Cox regression analysis by using the group with serum iPTH 150–299 pg/mL as the reference group. A $p < 0.05$ was considered statistically significant.

**Results**

**Baseline demographic and clinical characteristics of the study population**

The total study sample surveyed included 362 incident HD patients. After excluding 10 patients with inadequate clinical or laboratory data and 6 patients who were not willing to participate, 346 hemodialysis patients were included in the final analysis. The overall enrollment rate was 95.58%. The mean age of participants was 62.08 ± 14.56 years (30–85 years), 182 patients (52.60%) were men. The primary etiology of ESRD was diabetic nephropathy ($n = 128$, 36.99%), followed by chronic glomerulonephritis ($n = 125$, 36.13%), hypertensive renal disease ($n = 37$, 10.69%), chronic
Table 1. Baseline characteristics of study participants.

| Characteristics                  | Total (n = 346) | iPTH < 150 pg/mL (n = 110) | 150 ≤ iPTH ≤ 300 pg/mL (n = 94) | iPTH > 300 pg/mL (n = 142) | P-value |
|----------------------------------|----------------|----------------------------|---------------------------------|-----------------------------|---------|
| Age, (years)                     | 62.08 ± 14.56  | 66.02 ± 9.99               | 61.68 ± 13.93                  | 59.25 ± 14.71               | <0.001  |
| Male sex, n (%)                  | 182 (52.60)    | 56 (50.91)                 | 58 (61.70)                      | 68 (47.89)                  | 0.105   |
| Smoking, n (%)                   | 106 (30.64)    | 29 (26.36)                 | 32 (34.04)                      | 45 (31.69)                  | 0.465   |
| BMI (kg/m²)                      | 22.67 ± 3.42   | 22.28 ± 3.63               | 22.09 ± 3.44                    | 23.34 ± 3.13                | 0.008   |
| Diabetes mellitus, n (%)         | 194 (56.07)    | 86 (78.18)                 | 46 (48.94)                      | 62 (43.66)                  | <0.001  |
| Hypertension, n (%)              | 294 (84.97)    | 92 (83.64)                 | 74 (78.72)                      | 128 (90.14)                 | 0.050   |
| Medication use                   |                |                            |                                 |                             |         |
| Phosphate binders, n (%)         | 204 (58.96)    | 52 (47.27)                 | 48 (51.06)                      | 104 (73.24)                 | <0.001  |
| Vitamin D, n (%)                 | 146 (42.20)    | 50 (45.46)                 | 36 (38.30)                      | 60 (42.25)                  | 0.587   |
| Cinacalcet, n (%)                | 37 (10.69)     | 11 (10.00)                 | 10 (10.64)                      | 16 (11.27)                  | 0.949   |
| Vascular access type             |                |                            |                                 |                             |         |
| Arteriovenous fistula, n (%)     | 170 (49.13)    | 50 (45.46)                 | 51 (54.26)                      | 69 (48.59)                  | 0.450   |
| Catheter, n (%)                  | 174 (50.30)    | 59 (53.64)                 | 42 (44.68)                      | 73 (51.41)                  | 0.418   |
| Other, n (%)                     | 2 (0.58)       | 1 (0.91)                   | 1 (1.06)                        | 0                           | 0.491   |
| Laboratory parameters            |                |                            |                                 |                             |         |
| Hemoglobin (g/L)                 | 110.92 ± 16.20 | 107.35 ± 15.91             | 111.43 ± 15.61                  | 113.37 ± 16.42              | 0.013   |
| Albumin (g/L)                    | 37.82 ± 4.50   | 34.99 ± 4.14               | 38.09 ± 4.94                    | 39.83 ± 3.14                | <0.001  |
| Triglycerides (mmol/L)           | 20.8 ± 1.14    | 1.97 ± 0.89                | 1.87 ± 1.05                     | 2.30 ± 1.31                 | 0.009   |
| Total cholesterol (mmol/L)       | 4.3 ± 1.04     | 4.55 ± 1.00                | 4.20 ± 1.25                     | 4.25 ± 0.90                 | 0.028   |
| hs-CRP (mg/L)                    | 7.9 ± 5.53     | 10.18 ± 7.46               | 7.02 ± 4.45                     | 6.79 ± 3.59                 | <0.001  |
| Calcium (mmol/L)                 | 2.23 ± 0.20    | 2.25 ± 0.17                | 2.22 ± 0.20                     | 2.23 ± 0.21                 | 0.405   |
| Phosphorus (mmol/L)              | 1.98 ± 0.63    | 1.54 ± 0.35                | 1.84 ± 0.61                     | 2.40 ± 0.55                 | <0.001  |
| iPTH (pg/mL)                     | 259 (118.448)  | 81 (51.116)                | 220 (173.280)                   | 541 (393.646)               | <0.001  |
| 25 (OH)D (mg/mL)                 | 9.25 ± 3.71    | 9.66 ± 3.45                | 8.60 ± 3.39                     | 9.37 ± 4.07                 | 0.114   |
| eGFR (ml/min/1.73 m²)            | 6.72 ± 0.587   | 6.64 ± 0.611               | 6.756 ± 0.509                   | 6.724 ± 0.587               | 0.321   |
| sp Kt/V                          | 1.39 ± 0.25    | 1.34 ± 0.21                | 1.40 ± 0.24                     | 1.42 ± 0.27                 | 0.036   |

Data were presented as mean ± SD or median (interquartile range) for continuous variables, and number (%) for categorical variables. BMI: body mass index; hs-CRP: high sensitive C-reactive protein; iPTH: intact parathyroid hormone; 25 (OH)D: 25-hydroxy vitamin D.

The optimal serum iPTH range associated with the lowest risk of mortality

In the sensitivity analysis, we further divided the patients into six serum iPTH groups. Multivariate adjusted Cox regression analysis showed that patients with serum iPTH ≥ 750 pg/mL, 600–749 pg/mL, 450–599 pg/mL had significantly higher risk of all-cause mortality and cardiovascular mortality compared with those with serum iPTH in the range of 150–299 pg/mL, while patients with iPTH 300–449 pg/mL had no significant difference (Table 3, Figures 1 and 2).

Discussion

In this prospective observational study, we found that the lower level of serum calcium, a higher level of tubulointerstitial nephropathy (n = 33, 9.54%), and others (n = 23, 6.65%). The dialyzers with polycrylonitrile, polysulfone, polycarbonate membranes used in the hemodialysis treatment were 75.50%, 13.80%, and 10.70%, respectively. The average treatment session length was 3.85 ± 0.22 h. Calcium dialysate concentration was 1.5 mmol/L. The mean iPTH levels were 332.40 ± 296.56 pg/mL (10–1921 pg/mL). 110 patients (31.79%) were categorized as iPTH < 150 pg/mL group, 94 patients (27.17%) as 150 ≤ iPTH ≤ 300 pg/mL group, and 142 patients (41.04%) as iPTH > 300 pg/mL group. The baseline characteristics were shown in Table 1. The age, BMI, the proportion of patients with diabetes mellitus, proportion of used phosphate binders, blood hemoglobin, serum albumin, triglycerides, total cholesterol, hs-CRP, phosphorus, and Kt/V differed among the three groups. In contrast, there were no significant differences among the groups in terms of gender, smoking habit, prevalence of hypertension, the type of vascular access, serum calcium, 25(OH)D, and eGFR.

Association of serum iPTH levels and mortality

The median follow-up was 58 months. There were 157 (45.38%) cases of death during the follow-up. The primary causes of death were CVD (109, 69.43%), followed by infection (25, 15.92%), and other diseases caused by malignancy, chronic obstructive lung disease, gastrointestinal bleeding, and others (23, 14.65%). Table 2 presented the risk factors associated with all-cause mortality and CVD mortality (Supplementary Table). By using the group with serum iPTH 150–300 pg/mL as the reference group, multivariate adjusted Cox regression analysis showed that either iPTH < 150 pg/mL or iPTH > 300 pg/mL were independently associated with higher hazard ratio for all-cause mortality (HR 4.022, 95% CI 2.493–6.489, p < 0.001 and HR 1.752, 95% CI 1.008–3.044, p = 0.049, respectively) and CVD mortality (HR 4.729, 95% CI 2.535–8.822, p < 0.001 and HR 1.867, 95% CI 1.007–3.565, p = 0.049, respectively).
serum phosphorus, and a lower or higher level of serum iPTH of the incident HD patients were associated with all-cause mortality and CVD mortality even after adjustment of confounding factors. These findings suggested a U-shaped association between serum iPTH and mortality. Furthermore, we demonstrated that the

### Table 2. Multivariable Cox regression analyses for the risk factors of mortality.

| Characteristics | All-cause mortality | | CVD mortality | |
|-----------------|---------------------|---------------------|---------------------|
|                 | HR (95%CI)          | p-Value             | HR (95%CI)          | p-Value             |
| Age, (years)    | 1.025 (1.010–1.039) | 0.001               | 1.032 (1.015–1.050) | <0.001              |
| History of      |                     |                      |                     |
| Diabetes        | 1.658 (1.115–2.466) | 0.013               | 2.934 (1.688–5.100) | <0.001              |
| Hypertension    |                     |                      |                     |
| Vitamin D used  | 0.573 (0.370–0.888) | 0.013               | 2.540 (1.315–4.908) | 0.006               |
| sp Kt/V         | 0.089 (0.038–0.208) | <0.001              | 0.048 (0.018–0.129) | <0.001              |
| Hemoglobin (g/L)| 0.980 (0.969–0.991) | <0.001              | 0.975 (0.961–0.988) | <0.001              |
| Albumin (g/L)   | 0.923 (0.883–0.965) | <0.001              |                     |                      |
| Calcium         |                     |                      |                     |
| <2.10 mmol/L    | 1.699 (1.162–2.485) | 0.006               |                     |                      |
| 2.10–2.37 mmol/L| 1.000 (reference) |                     |                     |                      |
| >2.37 mmol/L    | 0.920 (0.602–1.405) | 0.698               |                     |                      |
| Phosphorus      |                     |                      |                     |
| <1.13 mmol/L    | 0.702 (0.454–1.087) | 0.112               | 0.957 (0.580–1.484) | 0.092               |
| 1.13–1.78 mmol/L| 1.000 (reference) |                     | 1.000 (reference) |                     |
| >1.78 mmol/L    | 1.674 (1.117–2.507) | 0.013               | 1.560 (1.098–2.484) | 0.014               |
| iPTH            |                     |                      |                     |
| <150 pg/mL      | 4.022 (2.493–6.489) | <0.001              | 4.729 (2.535–8.822) | <0.001              |
| 150–300 pg/mL   | 1.000 (reference) |                     | 1.000 (reference) |                     |
| >300 pg/mL      | 1.752 (1.008–3.044) | 0.047               | 1.867 (1.007–3.565) | 0.049               |

Model was adjusted for age, gender, BMI, comorbidities of diabetes and hypertension, medications (phosphate binders, vitamin D, and Cinacalcet), vascular access type, the serum level of hemoglobin, albumin, triglycerides, total cholesterol, hs-CRP, calcium, phosphate, iPTH, 25 (OH)VitD, eGFR, and sp Kt/V. CVD: cardiovascular disease; HR: hazard ratio; CI: confidence interval; iPTH: intact parathyroid hormone.

### Table 3. Multivariable Cox regression analyses for mortality according to the different range of serum iPTH.

| iPTH (pg/mL) | All-cause mortality | | CVD mortality | |
|--------------|---------------------|---------------------|---------------------|
|              | No. (%) of event | HR (95%CI) | p-Value | No. (%) of event | HR (95%CI) | p-Value |
| <150         | 82 (74.55) | 4.022 (2.493–6.489) | <0.001 | 56 (50.91) | 4.729 (2.535–8.822) | <0.001 |
| 150–299      | 28 (29.79) | reference | 1.000 | 15 (15.96) | reference | 1.000 |
| 300–449      | 20 (33.33) | 1.614 (0.861–3.027) | 0.135 | 11 (18.33) | 1.373 (0.603–3.127) | 0.450 |
| 450–599      | 7 (23.33) | 3.475 (1.270–9.505) | 0.015 | 7 (23.33) | 7.16 (2.475–12.735) | <0.001 |
| 600–749      | 8 (30.77) | 3.605 (1.416–9.177) | 0.007 | 8 (30.77) | 6.817 (2.594–13.912) | <0.001 |
| ≥750         | 12 (46.15) | 5.016 (2.278–11.043) | <0.001 | 12 (46.15) | 11.745 (4.726–27.187) | <0.001 |

Model was adjusted for age, gender, BMI, comorbidities of diabetes and hypertension, medications (phosphate binders, vitamin D, and Cinacalcet), vascular access type, the serum level of hemoglobin, albumin, triglycerides, total cholesterol, hs-CRP, calcium, phosphate, iPTH, 25 (OH)VitD, eGFR, and sp Kt/V. CVD: cardiovascular disease; HR: hazard ratio; CI: confidence interval; iPTH: intact parathyroid hormone.

### Figure 1. Multivariate adjusted hazard ratio (95% CI) for all-cause mortality according to the levels of serum iPTH. iPTH: intact parathyroid hormone; HR: hazard ratio; CI: confidence interval.
optimal serum iPTH for a relatively lower risk of all-cause mortality and CVD mortality were from 150 pg/mL to 450 pg/mL in those patients. Our result provided evidence for the proper range of serum iPTH among the incident HD patients.

Previous observational data suggested an association between abnormal biochemical markers of mineral metabolism and death [18–22]. However, the results of these studies were inconsistent [23–28]. Covic et al. [29] made a meta-analysis with 19 studies that assessed the association between disturbances in biochemical parameters and all-cause mortality among patients on dialysis. They found that elevated values in certain biochemical parameters, specifically the serum levels of iPTH, calcium, and phosphorus, as well as very low values of phosphorus were associated with an increase in all-cause mortality. In contrast to Covic et al., Palmer et al. [30] concluded from their meta-analysis that calcium and PTH did not have statistically significant associations with mortality, and only elevated serum phosphorus was related to mortality. The authors noticed that the studies were too methodologically diverse to permit an appropriate meta-analysis. Most importantly, both of these studies assumed a linear relationship between the serum levels of the three biochemical parameters and all-cause mortality in their meta-analysis, which could have biased the results of them. To avoid this limitation, we divided those three CKD-MBD biochemical parameters into three groups according to the recommendation from the K/DOQI guideline [10] and used them as categorical variables in the Cox regression analyses in our study. Our results indicated that elevated levels of serum phosphorus, decreased calcium, and either elevated or decreased serum iPTH were associated with death among these HD patients. Our study, in accordance with some previous studies [5,29,31] suggested that the relationship between the serum iPTH levels and mortality appeared as U-shaped, which indicated that the serum iPTH of the HD patients should keep in a certain range so that they could have a relatively lower risk of death.

Although the KDIGO guideline for CKD-MBD has suggested maintaining serum iPTH level in approximately two to nine times the upper normal limit, such a wide range of serum iPTH suggestion may bring confusion in clinical practice and the recommendation level was only C, which calls for related supporting evidence on this issue. To clarify this uncertainty, we made a sensitivity analysis to determine the optimal serum iPTH levels for a lower risk of all-cause mortality and CVD mortality in our patients. Our findings showed a lower risk of death in patients with iPTH in the range of 150–450 pg/mL. This serum iPTH range was narrower than that of the KDIGO guideline. When the serum iPTH was greater than 450 pg/mL, the mortality increased significantly; similarly, the mortality was 4 folds in the group of patients with serum iPTH < 150 pg/mL compared with those whose serum iPTH was 150–299 pg/mL. Recently, Hong et al. [9] showed that patients with iPTH < 150 pg/mL (n = 582) had a higher risk of infection-related mortality in 1771 incident dialysis patients. Furthermore, Merle and colleagues showed that patients with iPTH levels < 2 times the upper limit of normal values for the measurement kit used induced by high dialysate calcium is an independent risk factor for CVD mortality in hemodialysis patients [25]. These

Figure 2. Multivariate adjusted hazard ratio (95% CI) for CVD mortality according to the levels of serum iPTH. iPTH: intact parathyroid hormone; HR: hazard ratio; CI: confidence interval.
data not only partially supported our results about the U-shaped relationship between serum iPTh and mortality but also reminded us that we should pay more attention to prevent adverse outcomes among patients who have lower levels of serum iPTh.

There are several limitations to this study. First, as a prospective single-center study, it might have introduced selection bias, and the results should be carefully extrapolated to other HD patients. However, single-center study has some advantages of the similarity of the quality control in the whole process of the study. Second, we did not assess other biochemical markers related to CKD-MBD, such as fibroblast growth factor-23, which might cause interaction with the current biomarkers like serum calcium and phosphorus, and these data should be added in the future study. Thirdly, we only used the entry data to assess the association of CKD-MBD-related biomarkers (serum calcium, phosphate, and iPTh) with mortality, perhaps the time-average values of these parameters would give us a more meaningful hint about the relationship between CKD-MBD and adverse outcomes. Finally, causality cannot be inferred in this observational study. Interventional studies are needed to further clarify whether the restriction of serum iPTh at a certain optimal level could be a benefit to reduce the mortality among those patients. Regardless of these study limitations, several strengths of the present study are worth highlighting. Our observations are of importance as this is a prospective observational study about the relationship between serum iPTh level and all-cause mortality and CVD mortality in Chinese patients undergoing hemodialysis. The results were based on observation over a long period of follow-up (median follow-up of 58 months). To the best of our knowledge, it is conducted to date with the longest follow-up period examining the optimal serum iPTh level with improved outcomes among Chinese incident HD patients.

Conclusion

In the current study, we conclude that the relationship between serum iPTh and mortality appears to be a U-shaped curve. The optimal serum iPTh level which confers the lowest risk of all-cause mortality and CVD mortality ranges from 150 pg/mL to 450 pg/mL in this group of Chinese incident HD patients. We should pay more attention to HD patients whose serum iPTh level are extremely low or high, even in the range of serum iPTh level provided by the KIDGO guideline.

Acknowledgments

We thank all staff of the Blood Purification Center of Beijing Shijitan Hospital.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

This research was funded by the Beijing Municipal Science & Technology commission national key research and development plan matching project [Z161100002616005].

ORCID

Xiaoling Zhou http://orcid.org/0000-0002-8820-5195

References

[1] Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2018–2208.
[2] Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005;67(3):1179–1187.
[3] Fukagawa M, Kido R, Komaba H, et al. Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding. Am J Kidney Dis. 2014;63(6):979–987.
[4] Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) guideline update: what’s changed and why it matters. Kidney Int. 2017;92(1):26–36.
[5] Floege J, Kim J, Ireland E, et al. Serum iPTh, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant. 2011;26(6):1948–1955.
[6] Natoli JL, Boer R, Nathanson BH, et al. Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysis. BMC Nephrol. 2013;14:88.
[7] Kimata N, Albert JM, Akiba T, et al. Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: the Japan dialysis outcomes and practice patterns study. Hemodial Int. 2007;11(3):340–348.
[8] Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008;52(3):519–530.
[9] Hong YA, Kim JH, Kim YK, et al. Low parathyroid hormone level predicts infection-related mortality in incident dialysis patients: a prospective cohort study. Korean J Intern Med. 2020;35(1):160–170.

[10] National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1–S201.

[11] Janjua TK, Mukhtar KN, Naveed AK, et al. Frequency of maintenance haemodialysis patients meeting K/DOQI criteria for serum calcium, phosphorus, calcium-phosphate product and PTH levels; a single institutional experience from Pakistan: a cross sectional study. Pan Afr Med J. 2019;33:183.

[12] Wei M, Taskapan H, Esbæi K, et al. K/DOQI guideline requirements for calcium, phosphate, calcium-phosphate product, and parathyroid hormone control in dialysis patients: can we achieve them? Int Urol Nephrol. 2007;38(3–4):739–743.

[13] Toussaint ND, Pedagogos E, Beavis J, et al. Improving CKD-MBD management in haemodialysis patients: barrier analysis for implementing better practice. Nephrol Dial Transplant. 2011;26(4):1319–1326.

[14] Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;76(13):S1–S130.

[15] Cozzolino M. CKD-MBD KDIGO guidelines: how difficult is reaching the ‘target’? Clin Kidney J. 2018;11(1):70–72.

[16] Fouque D, Roth H, Darné B, et al. Achievement of Kidney Disease: Improving Global Outcomes mineral and bone targets between 2010 and 2014 in incident dialysis patients in France: the Photo-Graphe3 study. Clin Kidney J. 2018;11(1):73–79.

[17] Teo BW, Xu H, Wang D, et al. GFR estimating equations in a multiethnic Asian population. Am J Kidney Dis. 2011;58(1):56–63.

[18] Cozzolino M, Messa P, Brancaccio D, et al. Achievement of NKF/K-DOQI recommended target values for bone and mineral metabolism in incident haemodialysis patients: results of the FARO-2 cohort. Blood Purif. 2014;38(1):37–45.

[19] Villa-Bellosta R, Rodriguez-Osorio L, Mas S, et al. A decrease in intact parathyroid hormone (iPTH) levels is associated with higher mortality in prevalent haemodialysis patients. PLoS One. 2017;12(3):e0173831.

[20] Soohoo M, Feng M, Obi Y, et al. Changes in markers of mineral and bone disorders and mortality in incident haemodialysis patients. Am J Nephrol. 2016;43(2):85–96.

[21] Soleymanian T, Niyazi H, Noorbakhsh Jafari Dehkordi S, et al. Predictors of clinical outcomes in hemodialysis patients: a multicenter observational study. Iran J Kidney Dis. 2017;11(3):229–236.

[22] Rivara MB, Ravel V, Kalantar-Zadeh K, et al. Uncorrected and albumin-corrected calcium, phosphorus, and mortality in patients undergoing maintenance dialysis. JASN. 2015;26(7):1671–1681.

[23] Asada S, Yokoyama K, Miyakoshi C, et al. Relationship between serum calcium or phosphate levels and mortality stratified by parathyroid hormone level: an analysis from the MBD-5D study. Clin Exp Nephrol. 2020;24(7):630–637.

[24] Avram MM, Mittman N, Myint MM, et al. Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis. 2001;38(6):1351–1357.

[25] Merle E, Roth H, London GM, et al. Low parathyroid hormone status induced by high dialysate calcium is an independent risk factor for cardiovascular death in hemodialysis patients. Kidney Int. 2016;89(3):666–674.

[26] Lee SA, Lee MJ, Ryu GW, et al. Low serum intact parathyroid hormone level is an independent risk factor for overall mortality and major adverse cardiac and cerebrovascular events in incident dialysis patients. Osteoporos Int. 2016;27(9):2717–2726.

[27] Fukushima S, Fukuhara S, Shimizu S, et al. Population-level associations of achievement of targets for bone-mineral markers with survival in haemodialysis patients with mildly elevated intact-PTH levels: a case-cohort study. Sci Rep. 2019;9(1):11301.

[28] Waziri B, Musenge E, Duarte R, et al. Associations of plasma fibroblast growth factor 23 and other markers of chronic kidney disease-Mineral and bone disorder with all-cause mortality in South African patients on maintenance dialysis: a 3-year prospective cohort study. PLoS One. 2019;14(5):e0216656.

[29] Covic A, Kothawala P, Bernal M, et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant. 2009;24(5):1506–1523.

[30] Palmer SC, Hayen A, Macaskill P, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011;305(11):1119–1127.

[31] Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70(4):771–780.